Frank J. Williams - 01 Feb 2023 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Role
Director
Signature
/s/ Jonathan Weinberg, Attorney-in-fact
Issuer symbol
EVH
Transactions as of
01 Feb 2023
Net transactions value
-$3,114,865
Form type
4
Filing time
03 Feb 2023, 16:05:17 UTC
Previous filing
05 Jan 2023
Next filing
02 Mar 2023
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Frank J. Williams filed Form 4 for Evolent Health, Inc. (EVH) on 03 Feb 2023."

Quick Takeaways

  • This page summarizes Frank J. Williams's Form 4 filing for Evolent Health, Inc. (EVH).
  • 4 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 03 Feb 2023, 16:05.

What Changed

  • Previous filing in this sequence was filed on 05 Jan 2023.
  • Current net transaction value: -$3,114,865.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVH Class A Common Stock Options Exercise $422,400 +110,000 +18% $3.84* 736,479 01 Feb 2023 Direct F1, F2
transaction EVH Class A Common Stock Sale $3,488,275 -108,500 -15% $32.15 627,979 01 Feb 2023 Direct F1, F2, F3
transaction EVH Class A Common Stock Sale $48,990 -1,500 -0.24% $32.66 626,479 01 Feb 2023 Direct F1, F2, F4
holding EVH Class A Common Stock 66,064 01 Feb 2023 See footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVH Class A Common Stock Option (right to buy) Options Exercise $0 -110,000 -92% $0.000000 9,060 01 Feb 2023 Class A Common Stock 110,000 $3.84 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.
F2 Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.630 to $32.625, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.630 to $32.740, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Shares held of record by the Frank Williams Irrevocable Trust. Mr. Williams serves as the Trustee of the Frank Williams Irrevocable Trust.
F6 The Class A Common Stock Options exercised vested on December 1, 2017.

Sponsored